Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

Albany Molecular Research, Inc.. (2/7/17). "Press Release: AMRI Announces Strategic Alliance to Advance Mass Spectrometry Capabilities for Drug Discovery". Albany, NY.

Region Region Washington, D.C.
  Country United States (USA)
Organisations Organisation Albany Molecular Research Inc. (Nasdaq: AMRI)
  Group Albany Molecular (AMRI) (Group)
  Organisation 2 Bruker Daltonik GmbH
  Group Bruker (Group)
Products Product MALDI PharmaPulse™ HTS Solution for Drug Discovery
  Product 2 drug screening (HTS)
Index terms Index term Albany Molecular–Bruker: mass spectrometer, 201702 supply MALDI PharmaPulse system to AMRI by Bruker Daltonics + HighRes Biosolutions
  Index term 2 Bruker–Albany Molecular: mass spectrometry, 201702– collab developm of HTS applications using MALDI PharmaPulse system from Bruker + HighRes
Persons Person Carr, Grant (Albany Molecular 201702 Senior Director Lead Discovery)
  Person 2 Speir, Paul (Bruker 200905 VP FTMS Bruker Daltonics)

AMRI (NASDAQ: AMRI), a global contract research and manufacturing organization working to improve patient outcomes and quality of life, has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high throughput mass spectrometry (MS) for drug discovery.

AMRI has acquired the new MALDI PharmaPulse system from Bruker Daltonics and HighRes Biosolutions. The system will be deployed at AMRI's Integrated Drug Discovery Center and, in accordance with the terms of the alliance, Bruker Daltonics and HighRes Biosolutions will provide training and consulting to AMRI biologists to aid them in their development of protocols on the system that can be used for high throughput screening drug discovery programs.

"We see incredible potential for this technology at AMRI's Integrated Drug Discovery Center as this is the first technology to allow MS-based screening and analysis at the output required for cost-effective hit discovery," said Christopher Conway, senior vice president, Discovery and Development Services, at AMRI. "Accelerating all phases of drug discovery is critical to our customers. We will be better able to develop protocols using AMRI's novel, label-free screening assays and extend the utility of the MALDI PharmaPulse technology to complex cell-based assays for the identification of potential new drugs to meet a variety of unmet needs."

With technical support from these partners, AMRI will apply advanced laboratory automation and MS technologies to provide next generation, high throughput, label-free screening by MS (PharmaPulse). These improved assays and screening strategies will accelerate and enable development of drugs to treat complex diseases that are poorly served by current therapies. AMRI will apply its biological understanding and expertise to extend the utility of MALDI PharmaPulse technology to encompass complex cell-based assays and an expanded portfolio of MS-based biochemical assays.

"The protocols we can develop by applying the latest MS technologies to assay development have enormous potential for many disease areas, including such challenging areas as Alzheimer's disease and other neurological diseases," said Grant Carr, Ph.D., senior director, lead discovery, at AMRI. "The extreme sensitivity of Bruker's MALDI-TOF technology enables us to execute thousands of assays an hour while providing a level of information that often exceeds traditional screening assays. When coupled with the HighRes' automation and process integration capabilities embodied in the MALDI PharmaPulse platform, we anticipate that this technique will enable entirely new avenues of drug discovery research."

"The MALDI PharmaPulse (MPP) solution is a game-changer for high throughput drug screening," said Paul Speir, senior vice president at Bruker Daltonics. "Combining true label-free detection with ultra-high speed MS analysis, MPP is designed to accelerate drug discovery and development. We are excited to be working with AMRI in the development of new reference assay protocols that pharma customers can customize and use."

Pharmaceutical companies require high throughput assay technologies to identify "Hits", the drug development starting points, from large collections of compounds. MALDI PharmaPulse systems combine Bruker's MALDI-TOF mass spectrometers with high throughput robotics and software from HighRes Biosolutions. The combination provides the first MS-based screening system able to screen > 10,000 test samples per day in Hit discovery mode and complete Hit discovery in a timely, cost effective manner using MS technology. AMRI has targeted a throughput of 100,000 test samples per day to match the requirements of clients refusing to compromise on screen quality.

Connect with the AMRI team at SLAS, from Feb 4-8, Washington, DC, Booth 816. Contact us to set up a meeting.

About AMRI

Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the life sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, key business segments include Discovery and Development Services, Active Pharmaceutical Ingredients, Drug Product, and Fine Chemicals. For more information, please visit or follow AMRI on Twitter (@amriglobal).

AMRI Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential benefits of mass spectrometry-based screening technology and its impact on drug discovery, AMRI's ability to leverage such technology, the expected demand from customers and the potential benefit to AMRI's Discovery and Development Services business. Readers should not place undue reliance on these forward-looking statements. AMRI's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which AMRI may not be able to predict and may not be within AMRI's control. Factors that could cause such differences include, but are not limited to, the ability of AMRI to hire and retain qualified biologists to develop assay protocols using the mass spectrometry-based screening technology, the risk of a decrease in customers' demand for AMRI's drug discovery research services, as well as those risks discussed in AMRI's Annual Report on Form 10-K for the year ended December 31, 2015 as filed with the SEC on March 30, 2016, the Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 as filed with the SEC on August 5, 2016 and AMRI's other SEC filings.

Record changed: 2023-06-05


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for Albany Molecular (AMRI) (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture Demy-Colton BioFuture 2023 NYC Game Changers 650x300px

» top